How to Group Multiple Models for Canadian Medical Device Registration?

For medical device registration in Canada, grouping multiple models into one application is permitted under Health Canada's regulations, provided the models share the same fundamental design and intended use, and differences do not affect safety or effectiveness. Manufacturers must first identify the device's classification (Class II/III/IV require a Medical Device License, Class I only requires establishment listing). For multi-model grouping, assess similarities in intended use, operating principle, materials, performance, sterilization, and labeling. Identical or minor differences can be grouped. Key evidence includes a comparison table, risk management report (ISO 14971), performance validation (showing no impact on safety/effectiveness), clinical evaluation (if applicable), and ISO 13485 or MDSAP certification. Common errors include merging models with significant differences, inadequate justification, neglecting software version control, and missing critical component variations. Manufacturers must prepare a differential analysis report, grouping justification, authorized representative documents (for non-Canadian manufacturers), and a post-market surveillance plan. For multi-country registrations, CE/FDA documentation can be reused, but Canada-specific requirements (e.g., bilingual labels, MDSAP certification) must be met.

Applicable Scenarios and Core Issues

When submitting a medical device registration to Health Canada, manufacturers often face a series of models with multiple variants (e.g., different sizes, configurations, software versions, material compositions). Submitting each model individually increases costs and timeline. Thus, grouping is efficient but must comply with the Canadian Medical Devices Regulations (SOR/98-282). The core question: how to determine whether multiple models belong to the same 'device family' and share one application?

Health Canada's guidance (e.g., MDG-2) states that models must be of the same fundamental design and intended use, with differences only in factors that do not affect safety or effectiveness (e.g., size, color, non-functional accessories).

Registration Decision Logic

• Step 1: Confirm the product is a medical device. If not (e.g., general health products), no registration required.
• Step 2: Determine the risk class (I, II, III, IV) based on Health Canada rules. Class I requires only a Medical Device Establishment Licence (MDEL); Class II and above need a Medical Device Licence (MDL). Class III/IV also require a quality system certificate (MDSAP or ISO 13485 with supplement).
• Step 3: Identify if multiple models share the same fundamental design. This includes identical main structure, operating principle, intended clinical use, key materials, and sterilization method. For example, different sizes of the same disposable syringe (1 mL, 2 mL) can typically be grouped; a change from polypropylene to polycarbonate material would likely break the fundamental design.
• Step 4: Evaluate whether differences do not affect safety and effectiveness. Minor differences (e.g., packaging count, color, secondary material changes) are allowed, but must be supported by evidence showing unchanged biocompatibility, performance, and clinical safety. For instance, different catheter sizes may have different flow characteristics—validation data is required.
• Step 5: Leverage existing regulatory documentation (e.g., NMPA, CE, FDA) but adapt to Canada-specific requirements (e.g., bilingual labels, MDSAP certification).

Required Documentation and Evidence

A single technical file covering all models must include:

• Model Differential Analysis Table: Clearly list parameter differences and indicate if any affect safety or effectiveness.
• Risk Management Report (ISO 14971): Address hazards for all models, risk control measures, and justification that differences do not increase residual risk.
• Performance Validation Reports: Test data for key performance indicators (e.g., accuracy, strength, durability) covering worst-case models.
• Biocompatibility Assessment (ISO 10993): If materials change, provide test results or exemption rationale.
• Clinical Evaluation Report: Especially for Class III/IV, based on clinical data or literature.
• Bilingual Labels and Instructions: Provide Canadian French and English labels for all models; may use a template with differences noted.
• Authorized Representative Letter: For non-Canadian manufacturers, a written agreement designating a Canadian representative responsible for registration and post-market surveillance.
• Quality System Certificate: MDSAP is preferred; if not available, submit ISO 13485 with explanation (Health Canada may require additional review).
• Manufacturing Site Information: If models are produced at different sites, specify and validate each.

Common Errors

• Grouping models with different intended uses (e.g., diagnostic vs. therapeutic).
• Failing to provide substantive evidence that differences do not affect safety/effectiveness—mere statements are insufficient.
• Neglecting software version control: different software versions may constitute different models requiring separate evaluation.
• Missing critical component variations (e.g., catheter and guidewire combinations—changes to one component may require revalidation).
• Incomplete labeling coverage for all models, leading to deficiency letters.
• Expired or incomplete authorized representative documentation, and failure to submit a post-market surveillance plan.

Manufacturer Preparation Checklist

• List all models with intended use, clinical indications, and contraindications.
• Complete Canadian classification per Category I, II, III, IV rules.
• Create a 'model difference matrix' detailing variations (size, material, performance, packaging, software).
• For each difference, assess impact on safety/effectiveness and prepare supporting data (tests, literature).
• If using MDSAP, ensure the certificate covers all manufacturing sites; if not, consider obtaining it or prepare ISO 13485 with rationale.
• Designate a Canadian representative with a written agreement outlining responsibilities (submission, complaint handling, adverse event reporting).
• Prepare bilingual label samples (English/French); ensure all models are represented or use a generic template.
• Develop a post-market surveillance plan (PMS) including complaint handling, adverse event reporting, and vigilance procedures.
• Organize existing global registration files (CE, FDA, NMPA) and identify which parts can be reused vs. need localization.

AIMEILI Regulatory Interpretation and Business Impact

AIMEILI emphasizes that the most common misjudgment is the boundary of 'same fundamental design.' We recommend using a 'grouping matrix' tool at project initiation: map models by dimensions of intended use, operating principle, material category, sterilization method, etc. Only models where none of these dimensions change, or only minor changes occur, should be considered for grouping. Spending 1-2 days early on grouping analysis can avoid months of delays due to deficiencies.

Document Reuse: CE technical files (especially risk management and performance validation) are often directly transferable, but clinical evaluation may require additional Canadian ethnic/epidemiological data. MDSAP certification is more favored by Health Canada than ISO 13485 alone; if planning multi-country registration (e.g., US, Japan, Australia, Brazil), prioritize obtaining MDSAP.

Local Representative: The authorized representative is a critical control point. They handle not only registration but also change notifications, license renewals, and adverse event reporting. Maintain a strong relationship and clearly define certificate ownership and control rights in the contract. If changing representatives, notify Health Canada at least 90 days in advance and resubmit authorization documents; otherwise, the license may become invalid.

Multi-Country Strategy: For simultaneous registrations in Canada, Southeast Asia, Middle East, etc., create a 'core technical document package' containing universal information (e.g., performance testing, risk management summary, clinical evaluation overview), then add country-specific sections (e.g., label language, local clinical data references, copy of existing registration certificates). This significantly reduces repetitive work and deficiency risks.

Frequently Asked Questions

Q: If some models are already registered in China (NMPA) but not classified in Canada, how to quickly group them?
A: Reclassify each model per Canadian rules, then apply the 'same fundamental design' principle. If all models belong to the same NMPA registration unit and share the same intended use, they can generally be considered as having the same fundamental design, but Canadian-required evidence of differences must still be provided.

Q: After grouped registration, how to add a new model later?
A: If the new model falls within the existing grouped scope (i.e., fundamental design unchanged, differences do not affect safety/effectiveness), submit a change application to Health Canada to update the license. Best practice is to predefine a 'model series' scope in the initial technical file, describing possible future variants and control strategies.

Q: Does grouped registration require test reports for all models simultaneously?
A: No. Health Canada accepts representative model test data, but manufacturers must justify that the selected models represent the worst-case performance for all models (e.g., for different sizes, test the largest and smallest; for material ranges, choose the most extreme composition). Include an analysis report explaining the selection rationale.